

MAR 30 2007

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.: 10/799,016

Filed: March 11, 2004

For: LIPOPOLYSACCHARIDE A-2,3  
SIALYLTRANSFERASE OF  
CAMPYLOBACTER JEJUNI AND ITS  
USES

Customer No.: 20350

Confirmation No. 7215

Examiner: Portner, Virginia Allen

Technology Center/Art Unit: 1645

TERMINAL DISCLAIMERMail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Petitioner, National Research Council of Canada, Inc., is the owner of 100 percent interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,709,834 (filed January 29, 2002).

U.S. Patent No. 6,709,834 and the instant application were commonly owned at that time of invention of the subject matter claimed in U.S. Patent No. 6,709,834. Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and U.S. Patent No. 6,709,834 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full

statutory term as deemed in 35 U.S.C. 154 to 156 and 173 of a patent granted from U.S. Patent No. 6,709,834, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned (whose title is supplied below) is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 26 March 2007

By: Marielle Piché  
Name: Marielle Piché

Title: Secretary General, EXECUTIVE OFFICES  
Secretary General, Executive Offices  
Secretariat

Executive Offices  
National Research Council of Canada  
1200 Montreal Road  
M-58 Room W-312  
Ottawa, ON K1A 0R6

BLK:blk  
61003220 v1